Biohaven Pharmaceuticals CEO and leadership

Dr. Coric has more than 15 years of drug discovery and clinical development experience at Yale School of Medicine and Bristol-Myers Squibb. Within the pharmaceutical industry, Dr. Coric has expertise working across therapeutic areas including neuroscience, virology, oncology and immuno-oncology. Most recently, Dr. Coric was the immuno-oncology indication lead for neuro-oncology and glioblastoma. He has been involved in multiple drug development programs including marketed drugs such as ABILIFY® (aripiprazole; partial dopamine agonist), OPDIVO® (nivolumab; anti-PD1), YERVOY® (Ipilimumab; anti-CTLA-4), DAKLINZA® (daclatasvir; NS5A inhibitor) and SUNVEPRA® (asunaprevir; NS3 inhibitor). He has conducted numerous clinical trials in various illnesses including obsessive compulsive disorder, generalized anxiety disorder, major depression, schizophrenia, schizoaffective disorder, Alzheimer’s disease, hepatocellular carcinoma, and glioblastoma. Dr. Coric was the first to report the therapeutic effects of the glutamate-modulating agent riluzole in neuropsychiatric disorders (Coric et al., 2003; 2005; Sanacora et al., 2004) and led the first clinical trial employing cerebrospinal fluid biomarkers to identity and enrich for patients with Prodromal Alzheimer’s Disease while at Bristol-Myers Squibb (Coric et al 2015). Additionally, Dr. Coric spearheaded the design of and led the first global registrational trial using checkpoint inhibitors in glioblastoma. Dr. Coric is an Associate Clinical Professor of Psychiatry at the Yale School of Medicine and has over 50 peer-reviewed publications. He previously served as Chief of the Yale Clinical Neuroscience Research Unit, and Director of the Yale Obsessive-Compulsive Disorder Research Clinic. He has served as President of the Connecticut Psychiatric Society (an 800 member district branch of the American Psychiatric Association). Dr. Coric completed residency training at the Yale Psychiatry Residency Training Program, where he also served as the Program-Wide Chief Resident for the Yale Department of Psychiatry, and Chief Resident on the PTSD firm at the West-Haven Connecticut Veterans Administration Hospital. Dr. Coric earned his medical degree at Wake Forest University School of Medicine in North Carolina.

Mr. Jones has over 20 years of commercial experience in the healthcare industry and has held leadership roles of increasing responsibility at Takeda Pharmaceuticals, Inc., Bristol-Myers Squibb, Boehringer-Ingelheim, NitroMed and AstraZeneca. He has significant experience in mass market product launches, including Excedrin Migraine, Abilify, Farxiga, Pradaxa, and BiDil. BJ has successfully built and led diverse commercial teams committed to addressing unmet patient needs across various therapeutic areas, including neuroscience (migraine, schizophrenia, bipolar, depression), CV (CHF, atrial fibrillation), diabetes (type 2 - oral and injectable), respiratory, GI, and infectious disease. He holds a Bachelor of Science degree from the U.S. Air Force Academy, a Master of Science degree in Industrial Engineering from Texas A&M University and an MBA from Stanford Graduate School of Business. Prior to joining the pharmaceutical industry, BJ served in the U.S. Air Force and earned the rank of Major.

Dr. Stock has 30 years of clinical and drug development experience. After practicing psychiatry for 11 years she joined the pharmaceutical industry. Within the industry, Dr. Stock has spent the last 19 years at Bristol-Myers Squibb developingnumerous experimental agents across multiple therapeutic areas including neuroscience, oncology, immunology and cardiovascular. She has led numerous large and complex programs across all aspects of development including those leading to the marketing of products such as ABILIFY®, ORENCIA®, and EMPLICITI®. She is an experienced developer of both biologic and non-biologic compounds. Dr. Stock completed her residency at Payne Whitney Clinic, Cornell Medical Center and her fellowship in Child and Adolescent Psychiatry at Children’s Hospital National Medical Center in Washington D.C. She earned her medical degree at New York University School of Medicine.

Mr. Tilton has over 20 years of experience commercializing drug products and leading global pharmaceutical business units. He joined Biohaven from Alexion Pharmaceuticals, Inc. where he was an Executive Director and one of the founding commercial leaders responsible for the commercialization of multiple orphan drug indications. Mr. Tilton played a central role in the successful global launches of Soliris, as well as building operational infrastructure, for 4 orphan indication launches in over 30 countries for Alexion. Previously, Mr. Tilton held leadership roles of increasing responsibility at Pfizer, Agouron and Sanofi with therapeutic focus in the orphan, oncology and specialty markets. Mr. Tilton holds a Bachelor of Science degree in Business Administration from the University of South Carolina - Darla Moore School of Business.

Dr. Croop brings to Biohaven over 25 years of clinical drug development experience in a wide range of neuroscience programs. Board certified in Neurology by the American Board of Psychiatry and Neurology, he entered the pharmaceutical industry at DuPont Merck Clinical Research and Development. After joining Bristol-Myers Squibb through its acquisition of DuPont Pharma, he led a group responsible for First in Human, Phase I, and translational neuroscience clinical trials. More recently, he was a key member of the Eliquis (apixaban) Phase III clinical development and regulatory filing teams. His career includes successful marketing authorization applications for three New Chemical Entities with global approvals for multiple indications. A graduate of the University of Pennsylvania School of Medicine, he completed his internship in Medicine and residency in Neurology at the Hospital of the University of Pennsylvania.

Dr. Conway has 28 years of research experience examining the biology of pain mechanisms, including 17 years of pharma experience in drug discovery and development in positions of increasing responsibility at Bristol-Myers Squibb Company (BMS). Dr. Conway led BMS’s biology program identifying novel CGRP receptor antagonists which resulted in the discovery of rimegepant and BHV-3500, and was part of the original development team advancing rimegepant into the clinic. Dr. Conway’s extensive experience in the field of pain research has resulted in being an inventor on three granted U.S. patents for the treatment of pain. Dr. Conway was intimately involved in Neuroscience programs advancing biologic and small molecule assets, and held pivotal roles driving drug discovery efforts in pain. Dr. Conway is a tech-savvy researcher with a long track-record of successfully bringing advances in technology and data science into the lab to accelerate high-quality decision making in drug discovery programs. Prior to his time at BMS, Dr. Conway carried out postgraduate studies in the Anesthesiology Research Laboratory under the guidance of Dr. Tony Yaksh at the University of California San Diego where he studied the spinal pharmacology of pain mechanisms. Dr. Conway received his doctoral training in the Laboratory of Psychopharmacology under the tutelage of Dr. Loy Lytle where he earned a Ph.D. in Neuroscience from the University of California Santa Barbara and was first to systematically characterize maturational changes in the development of nociceptive (pain) mechanisms.

Dr. Coric has more than 15 years of drug discovery and clinical development experience at Yale School of Medicine and Bristol-Myers Squibb. Within the pharmaceutical industry, Dr. Coric has expertise working across therapeutic areas including neuroscience, virology, oncology and immuno-oncology. Most recently, Dr. Coric was the immuno-oncology indication lead for neuro-oncology and glioblastoma. He has been involved in multiple drug development programs including marketed drugs such as ABILIFY® (aripiprazole; partial dopamine agonist), OPDIVO® (nivolumab; anti-PD1), YERVOY® (Ipilimumab; anti-CTLA-4), DAKLINZA® (daclatasvir; NS5A inhibitor) and SUNVEPRA® (asunaprevir; NS3 inhibitor). He has conducted numerous clinical trials in various illnesses including obsessive compulsive disorder, generalized anxiety disorder, major depression, schizophrenia, schizoaffective disorder, Alzheimer’s disease, hepatocellular carcinoma, and glioblastoma. Dr. Coric was the first to report the therapeutic effects of the glutamate-modulating agent riluzole in neuropsychiatric disorders (Coric et al., 2003; 2005; Sanacora et al., 2004) and led the first clinical trial employing cerebrospinal fluid biomarkers to identity and enrich for patients with Prodromal Alzheimer’s Disease while at Bristol-Myers Squibb (Coric et al 2015). Additionally, Dr. Coric spearheaded the design of and led the first global registrational trial using checkpoint inhibitors in glioblastoma. Dr. Coric is an Associate Clinical Professor of Psychiatry at the Yale School of Medicine and has over 50 peer-reviewed publications. He previously served as Chief of the Yale Clinical Neuroscience Research Unit, and Director of the Yale Obsessive-Compulsive Disorder Research Clinic. He has served as President of the Connecticut Psychiatric Society (an 800 member district branch of the American Psychiatric Association). Dr. Coric completed residency training at the Yale Psychiatry Residency Training Program, where he also served as the Program-Wide Chief Resident for the Yale Department of Psychiatry, and Chief Resident on the PTSD firm at the West-Haven Connecticut Veterans Administration Hospital. Dr. Coric earned his medical degree at Wake Forest University School of Medicine in North Carolina.

Dr. Croop brings to Biohaven over 25 years of clinical drug development experience in a wide range of neuroscience programs. Board certified in Neurology by the American Board of Psychiatry and Neurology, he entered the pharmaceutical industry at DuPont Merck Clinical Research and Development. After joining Bristol-Myers Squibb through its acquisition of DuPont Pharma, he led a group responsible for First in Human, Phase I, and translational neuroscience clinical trials. More recently, he was a key member of the Eliquis (apixaban) Phase III clinical development and regulatory filing teams. His career includes successful marketing authorization applications for three New Chemical Entities with global approvals for multiple indications. A graduate of the University of Pennsylvania School of Medicine, he completed his internship in Medicine and residency in Neurology at the Hospital of the University of Pennsylvania.